ProfileGDS5678 / 1426846_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 70% 69% 66% 69% 68% 55% 62% 69% 71% 74% 72% 76% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3034169
GSM967853U87-EV human glioblastoma xenograft - Control 24.3309670
GSM967854U87-EV human glioblastoma xenograft - Control 34.2825169
GSM967855U87-EV human glioblastoma xenograft - Control 44.02466
GSM967856U87-EV human glioblastoma xenograft - Control 54.2652569
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1941468
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4697355
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7051762
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2870969
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4569171
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8013674
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.5768372
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0365776
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3845970